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COHORT
• 303 participants at AGES-Reykjavik follow-up visit had measurements of vertebral MF and hip/spine QCT.
• Participants with inadequate serum (N=3) or no MR (N=1) or use of bone-active medication (N=44) were excluded.
• 137 women and 118 men were included in analyses.
QUANTITATIVE COMPUTED TOMOGEAPHY (QCT)
• Scans were obtained for lumbar spine (L1 and L2, 120kVp, 150mAs, 1mm ST) and hip (140mAs, 1mm ST), mid-thigh (129kVp, 10mm ST) using 4-detector CT system (Sensation, Siemens Medical Systems, Erlangen, Germany).
• Cortical and trabecular volumetric BMDs (vBMDs) for vertebra and hip, vertebral compressive strength, hip geometry, subcutaneous fat at mid-femur and visceral fat at L4/L5 intervertebral space, and muscle attenuation at mid-thigh were calculated from QCT data.
PROTON MAGNETIC RESONANCE SPECTROSCOPY ( 1 H-MRS) FOR VERTEBRAL MF
• Single voxel Point Resolved Spectroscopy (PRESS) 1 H-MRS was acquired in vertebral bodies L1 to L4 using a 1.5 Tesla scanner (GE Healthcare, Milwaukee, WI) with an eight-channel spine coil (TR/TE = 2000/37ms, 64 averages without water suppression, voxel size = 12x12x20mm 3 ).
• Peak areas for water at 4.67ppm and fat at 1.3ppm were calculated using GE SAGE software. The average MFs (Fat/(Fat+Water)*100%) from all four vertebral levels were used in analyses.
DUAL-ENERGY X-RAY ABSORPTIOMETRY (DXA)
• Scans of lumbar spine, proximal femur and whole body were obtained with GE Healthcare Lunar iDXA scanner (software version 11.4).
ASSAY FOR SCLEROSTIN AND BONE TURNOVER MARKERS
• Serum was collected fasting and stored at -70°C.
• Sclerostin and markers for bone formation (amino-terminal propeptide of type 1 procollagen; P1NP) and bone resorption (serum C-terminal cross-linking telopeptide of type I collagen; CTX) were assayed in one batch.
STATISTICAL ANALYSIS
• Least square means of selected bone and body composition parameters were compared across tertiles of serum sclerostin level in a linear model adjusted for age, diabetes status, and BMI and ran separately by gender.
• P-values for linear trend across tertiles was used to assess association from models. 27.2 ± 3.6 28.0 ± 3.9 Sclerostin (ng/mL) 1.27 ± 0.41 0.84 ± 0.27 Results are shown either as n(%) or mean±SD.
Results
• As previous report showed a negative association between MF and BMD 1 , it is surprising that sclerostin is positively associated with both MF and BMD in men. However, higher MF was also associated with prevalent vertebral fracture in the same cohort 1 , independent of BMD. Sclerostin may be a marker of bone fragility, but this remains controversial.
• Previous reports on sclerostin and MF are not available. Further investigation is needed to understand the gender difference.
• Both trabecular and cortical vBMDs were positively associated with sclerostin, consistent with the only previous report on central QCT and sclerostin 2 .
• Previous studies have reported positive 3,4,5 or no 6,7 association between sclerostin and weight or BMI. Another previous study found no association between sclerostin and lean mass or fat mass 7 . Interestingly, sclerostin increases in response to weight loss 8 . Longitudinal studies are needed to fully understand the relationship between sclerostin and body composition.
• A limitation of this study is that the cohort lacks racial and age diversity. Contact Information
• Total hip cortical and trabecular vBMD increased significantly with higher sclerostin for men and women (Figure 1 ). • Spine trabecular vBMD increased significantly with higher sclerostin for women. The same positive trend, although not significant, was found in men (p=0.09) (Figure 1 ). • Areal BMDs measured by DXA increased significantly across sclerostin tertiles at spine, femoral neck, and total hip for both men and women.
• Vetebral cross-sectional area (CSA) non-significantly increased with higher sclerostin for both men (p=0.23) and women (p=0.16).
• PINP and CTX were negatively associated with sclerostin in women, but not men.
• MF increased significantly with higher sclerostin in men, but not women (Figure 2 ).
• There was a trend towards positive association between sclerostin and body mass index (BMI) in women (p=0.09), and weight in men (p=0.06).
• Total fat and lean mass measured by DXA and abdominal visceral and subcutaneous fat mass measured by QCT were not significantly associated with sclerostin levels (Figure 2 ). • Thigh muscle attenuation by QCT was not significantly associated with sclerostin levels (Figure 2 ). However, there was a positive trend for women (p=0.08).
P-values for trend shown. Adjusted for age, diabetes status, and BMI. 95% confidence levels shown as error bars.
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